AI Article Synopsis
- The study analyzed 31 cases of non-IgM lymphoplasmacytic lymphoma (LPL) and compared them with 93 cases of Waldenström macroglobulinemia (WM), matching participants by age, sex, and diagnosis year.
- Non-IgM LPL cases exhibited fewer mutations and shorter times to treatment compared to WM controls, but had higher chances of extramedullary disease.
- Despite these differences in clinical features and treatment options, both groups had similar response rates and overall survival outcomes.
Article Abstract
Cases of non-IgM lymphoplasmacytic lymphoma (LPL) are rare. We performed a case-control study comparing features and outcomes of 31 non-IgM LPL cases and 93 Waldenström macroglobulinemia (WM) controls matched by age, sex, and year of diagnosis. Odds of mutations were lower (odds ratio (OR) 0.22, = .05), and median time to treatment was shorter in cases than in controls (4 32 months; < .001). Odds of extramedullary disease were higher (OR 4.20, = .01), while odds of neuropathy (OR 0.22, = .25), and hyperviscosity (OR 0.26, = .26) were lower in cases than in controls. Odds of using chemoimmunotherapy were higher (OR 2.62, = .11) while odds of using proteasome inhibitors (OR 0.35, = .15) and BTK inhibitors (OR 0.17, = .21) were lower in cases than in controls. There were no differences in response and overall survival (OS) between cases and controls. Despite clinicopathological differences, response, and survival outcomes are similar between non-IgM LPL cases and WM controls.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2020.1719100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!